NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced five presentations, including two featured oral plenary presentations, on solriamfetol at SLEEP 2024, the 38th annual meeting of the American Academy of Sleep Medicine (AASM) and the Sleep Research Society (SRS), being held June 1-5, 2024, in Houston, Texas. "Cognitive functionin ...

NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced five presentations, including two featured oral plenary presentations, on solriamfetol at SLEEP 2024, the 38th annual meeting of the American Academy of Sleep Medicine (AASM) and the Sleep Research Society (SRS), being held June 1-5, 2024, in Houston, Texas. “Cognitive functioni ...

NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that data from its industry-leading portfolio of novel products for CNS disorders will be presented at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, being held May 28-31, 2024, in Miami Beach, Florida. The presentations include new data from post ...

NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in two upcoming investor conferences. The presentation details are as follows: RBC Capital Markets 2024 Global Healthcare Conference, on Tuesday, May 14, at 1:35 p.m. Eastern Time. Dr. Tabuteau will pa ...

NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in two upcoming investor conferences. The presentation details are as follows: RBC Capital Markets 2024 Global Healthcare Conference, on Tuesday, May 14, at 1:35 p.m. Eastern Time. Dr. Tabuteau will pa ...

Axsome Therapeutics, Inc. (AXSM) reported an adjusted loss of $1.00 per share for the first quarter of 2024, compared with a loss of 22 cents per share reported in the year-ago period. The Zacks Consensus Estimate was pegged at a loss of $1.20 per share.The above-adjusted loss excludes the impact of certain non-cash charges, including which the reported loss per share was $1.44 in the first quarter of 2024 compared with a loss of 26 cents per share reported in the year-ago quarter.The company reported total ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-37635 AXSOME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 45-4241907 (State or othe ...

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2024 Earnings Conference Call May 6, 2024 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - Chief Executive Officer Nick Pizzie - Chief Financial Officer Ari Maizel - Executive Vice President & Head, Commercial Mark Jacobson - Chief Operating Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Leonid Timashev - RBC Capital Markets Ash Verma - UBS Ram Selvaraju - H.C. Wainwright Marc Goodman - L ...

Exhibit 99.1 Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update Total 1Q 2024 net product revenue of $75.0 million, representing 160% year-over-year growth Auvelity® 1Q 2024 net product sales of $53.4 million, representing 240% year-over-year growth Sunosi® 1Q 2024 net product revenue of $21.6 million representing 64% year-over-year growth Contract executed with second large group purchasing organization (GPO) for potential coverage of Auvelity Positive pivotal Pha ...

Biotech stocks offer the opportunity to invest in life-saving treatments and drugs. So not only can you make massive gains but you are also investing in the advancement of modern medicine. But not all biotech companies are the same. Some are established pharmaceutical giants while others are pre-revenue startups that are banking on a drug breakthrough. What this means is that an FDA approval or denial can have major consequences on the stock. If you want to invest in biotech stocks, you will need to keep up ...